Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

26

description

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors. Brief Overview of NOACs. NOACs Important Comparative Features. Effect on NOAC Plasma Levels from D-D Interactions, and Recommendations. Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors. - PowerPoint PPT Presentation

Transcript of Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Page 1: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 2: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 3: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Sites of Action in Coagulation System

Novel Factor Xa and DT Inhibitors

Page 4: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Brief Overview of NOACs

Page 5: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

NOACsImportant Comparative Features

Page 6: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 7: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Effect on NOAC Plasma Levels from D-D Interactions, and Recommendations

Page 8: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 9: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Sites of Action in Coagulation System

Novel Factor Xa and DT Inhibitors

Page 10: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Brief Overview of NOACs

Page 11: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Ethnic Differences in Rate of ICH

Page 12: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Estimated Levels of Exposurein White and Japanese Patients

Page 13: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 14: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 15: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Primary Efficacy End Point (Stroke/SEE) mITT Population While on Treatment

Page 16: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Main Safety ResultsSafety Cohort on Treatment

Page 17: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors
Page 18: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Lower NOAC DoseClinical Implications

Page 19: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Incidence of Stroke or Systemic Embolism

Page 20: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Abbreviations

Page 21: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Abbreviations (cont)

Page 22: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Abbreviations (cont)

Page 23: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

References

Page 24: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

References (cont)

Page 25: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

References (cont)

Page 26: Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

References (cont)